Literature DB >> 26598018

Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.

S Sinha1, J Boysen1, M Nelson1, S L Warner2, D Bearss2, N E Kay1, A K Ghosh3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26598018      PMCID： PMC4879100          DOI： 10.1038/leu.2015.323

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors.

Authors:  Emanuela Moroni; Patrizia Dell'Era; Marco Rusnati; Marco Presta
Journal:  J Hematother Stem Cell Res       Date:  2002-02

2.  Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.

Authors:  Andrew Chase; Francis H Grand; Nicholas C P Cross
Journal:  Blood       Date:  2007-08-13       Impact factor: 22.113

Review 3.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus.

Authors:  C L Johnston; H C Cox; J J Gomm; R C Coombes
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

5.  The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.

Authors:  Asish K Ghosh; Charla Secreto; Justin Boysen; Traci Sassoon; Tait D Shanafelt; Debabrata Mukhopadhyay; Neil E Kay
Journal:  Blood       Date:  2010-12-06       Impact factor: 22.113

6.  Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.

Authors:  Sutapa Sinha; Justin Boysen; Michael Nelson; Charla Secreto; Steven L Warner; David J Bearss; Connie Lesnick; Tait D Shanafelt; Neil E Kay; Asish K Ghosh
Journal:  Clin Cancer Res       Date:  2015-02-11       Impact factor: 12.531

7.  FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.

Authors:  Abdel Kareem Azab; Feda Azab; Phong Quang; Patricia Maiso; Antonio Sacco; Hai T Ngo; Yang Liu; Yong Zhang; Brittany L Morgan; Aldo M Roccaro; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-04-26       Impact factor: 12.531

Review 8.  Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.

Authors:  Corine G M L'Hôte; Margaret A Knowles
Journal:  Exp Cell Res       Date:  2004-12-16       Impact factor: 3.905

9.  The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

Authors:  J Boysen; S Sinha; T Price-Troska; S L Warner; D J Bearss; D Viswanatha; T D Shanafelt; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528

10.  AXL mediates resistance to cetuximab therapy.

Authors:  Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; Neha Luthar; Mahmoud Toulany; Parkash S Gill; Ravi Salgia; Randall J Kimple; Deric L Wheeler
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701
View more
  7 in total

1.  SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis.

Authors:  Guru P Maiti; Sutapa Sinha; Hasan Mahmud; Justin Boysen; Mariana T Mendez; Sara K Vesely; Jennifer Holter-Chakrabarty; Neil E Kay; Asish K Ghosh
Journal:  Blood Cancer J       Date:  2021-05-17       Impact factor: 11.037

Review 2.  Targeting the TAM Receptors in Leukemia.

Authors:  Madeline G Huey; Katherine A Minson; H Shelton Earp; Deborah DeRyckere; Douglas K Graham
Journal:  Cancers (Basel)       Date:  2016-11-08       Impact factor: 6.639

Review 3.  AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.

Authors:  Siyang Yan; Niels Vandewalle; Nathan De Beule; Sylvia Faict; Ken Maes; Elke De Bruyne; Eline Menu; Karin Vanderkerken; Kim De Veirman
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

4.  Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance.

Authors:  Sutapa Sinha; Charla R Secreto; Justin C Boysen; Connie Lesnick; Zhiquan Wang; Wei Ding; Timothy G Call; Saad J Kenderian; Sameer A Parikh; Steven L Warner; David J Bearss; Asish K Ghosh; Neil E Kay
Journal:  Blood Cancer J       Date:  2021-02-18       Impact factor: 11.037

5.  AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.

Authors:  Irene Tirado-Gonzalez; Arnaud Descot; Devona Soetopo; Aleksandra Nevmerzhitskaya; Alexander Schäffer; Ivan-Maximilano Kur; Ewelina Czlonka; Carolin Wachtel; Ioanna Tsoukala; Luise Müller; Anna-Lena Schäfer; Maresa Weitmann; Petra Dinse; Emily Alberto; Michèle C Buck; Jonathan Jm Landry; Bianka Baying; Julia Slotta-Huspenina; Jenny Roesler; Patrick N Harter; Anne-Sophie Kubasch; Jörn Meinel; Eiman Elwakeel; Elisabeth Strack; Christine Tran Quang; Omar Abdel-Wahab; Marc Schmitz; Andreas Weigert; Tobias Schmid; Uwe Platzbecker; Vladimir Benes; Jacques Ghysdael; Halvard Bonig; Katharina S Götze; Carla V Rothlin; Sourav Ghosh; Hind Medyouf
Journal:  Cancer Discov       Date:  2021-06-08       Impact factor: 39.397

6.  HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells.

Authors:  Hasan Mahmud; Mariana Mendez; Bedabrata Mukhopadhyay; Jennifer Holter-Chakrabarty; Asish K Ghosh
Journal:  Oncotarget       Date:  2020-06-02

7.  Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma.

Authors:  Utkarsh Painuly; Vijay Ramakrishnan; Teresa Kimlinger; Linda Wellik; Jessica Haug; Wilson Gonsalves; Lintao Bi; Zhongxia Huang; S Vincent Rajkumar; Shaji Kumar
Journal:  Oncotarget       Date:  2018-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.